Amgen Stock Price, News & Analysis

Amgen Inc. (NASDAQ: AMGN) is a biotechnology company in the biological product manufacturing industry that focuses on discovering, developing, manufacturing and delivering medicines for serious diseases. According to the company, its medicines are used by millions of patients in their fight against some of the world's toughest diseases, with a portfolio and pipeline that span cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

More than 40 years ago, Amgen helped to establish the biotechnology industry. The company describes itself as using technology and human genetic data to push beyond what is known today, supporting the discovery and development of new therapies. Amgen trades on the Nasdaq Stock Market under the symbol AMGN and is part of the Manufacturing sector.

Business focus and therapeutic areas

Amgen states that it advances a broad and deep pipeline that builds on its existing portfolio of medicines. Its areas of focus include oncology, cardiovascular disease, bone health, inflammatory conditions and rare diseases. The company highlights work on medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases as central to its strategy.

In oncology, Amgen reports an extensive cancer portfolio and early discovery efforts. The acquisition of Dark Blue Therapeutics, a privately held biotechnology company based in the United Kingdom, adds an investigational small molecule that targets and degrades two proteins (MLLT1/3) associated with specific types of acute myeloid leukemia. Amgen indicates that this acquisition complements and extends its research in targeted protein degradation and leukemia therapeutics and is intended to strengthen its early oncology discovery efforts.

In cardiovascular disease, Amgen highlights Repatha (evolocumab), a PCSK9 inhibitor that lowers low-density lipoprotein cholesterol (LDL-C). The company reports that Repatha has been studied in large Phase 3 clinical trials, including the VESALIUS-CV trial, which evaluated the impact of LDL-C lowering on major adverse cardiovascular events in adults at high cardiovascular risk without prior heart attack or stroke. Amgen notes that Repatha is approved in many countries and has been used by millions of patients globally.

Amgen also emphasizes work in rare and autoimmune diseases. The company reports that UPLIZNA (inebilizumab-cdon), a humanized monoclonal antibody targeting CD19-positive B cells, has been approved in the United States for multiple indications, including anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, Immunoglobulin G4-related disease and generalized myasthenia gravis in certain adult patients. These approvals are based on clinical trials that evaluated efficacy and safety in defined patient populations.

Role in major equity indexes

Amgen states that it is one of the 30 companies that comprise the Dow Jones Industrial Average. It also notes that it is part of the Nasdaq-100 Index, which includes large non-financial companies listed on the Nasdaq Stock Market based on market capitalization. These index memberships position AMGN stock within widely followed U.S. equity benchmarks.

Recognition and corporate profile

The company reports that it has received external recognitions, including being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes. Amgen also notes its long-standing commitment to innovation and U.S. manufacturing, and has publicly discussed large-scale investments in manufacturing and research and development in the United States.

Amgen’s communications describe a business model centered on biopharmaceutical research, clinical development, large-scale biologics manufacturing and global commercialization of medicines. The company also indicates that it uses collaborations, acquisitions and licensing to expand its portfolio and pipeline, as illustrated by the Horizon acquisition and the acquisition of Dark Blue Therapeutics.

Investor communications and financial reporting

Amgen regularly reports its financial results and other material events through filings with the U.S. Securities and Exchange Commission (SEC). For example, Form 8-K filings dated August 5, 2025 and November 4, 2025 describe quarterly earnings press releases and the company’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income and Free Cash Flow. The company explains that these measures are used internally for budgeting, financial planning, resource allocation and evaluation of performance relative to incentive compensation targets.

According to these filings, Amgen adjusts GAAP results for acquisition-related expenses, restructuring and cost savings initiatives, and certain other items such as gains and losses on investments in equity securities and specific legal matters. The company states that it believes these adjustments provide supplementary information for evaluating ongoing business performance and liquidity.

Capital allocation and dividends

Amgen’s board of directors has declared cash dividends on its common stock. For example, in December 2025 the company announced a first quarter 2026 dividend per share, payable to stockholders of record on a specified date. In its disclosures, Amgen notes that business performance can affect or limit the ability of its board to declare dividends or the company’s ability to pay dividends or repurchase common stock.

Regulatory environment and risk factors

In multiple news releases and SEC-related disclosures, Amgen outlines factors that may affect its results. These include its ability to market new and existing products, clinical and regulatory developments, competition (including from biosimilars), manufacturing challenges, pricing pressure, reimbursement policies, government investigations, litigation, intellectual property disputes, tax law changes, supply chain dependencies, information technology security risks and broader economic conditions. The company notes that its research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government authorities.

AMGN stock context

As a Nasdaq-listed biotechnology issuer in the Manufacturing sector, Amgen Inc. is followed by investors who track biopharmaceutical innovation, large-cap healthcare equities and major U.S. stock indexes. The company’s communications emphasize a combination of established products, a pipeline of investigational therapies and ongoing investments in research, manufacturing and corporate development transactions.